SCYX - サイネクシス （SCYNEXIS Inc.）

SCYNEXIS, Inc. (NASDAQ:SCYX – Get Rating) – Equities research analysts at Cantor Fitzgerald boosted their FY2023 earnings per share estimates for SCYNEXIS in a research report issued to clients and investors on Monday, April 3rd. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of $1.31 per share for the year, […]

According to data from Benzinga Pro, during Q4, SCYNEXIS ''s (NASDAQ: SCYX ) reported sales totaled $1.40 million. Despite a 51.23% increase in earnings, the company posted a loss of $14.43 million. In Q3, SCYNEXIS brought in $1.56 million in sales but lost $29.58 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com

SCYNEXIS and GSK signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. Read our updated outlook here.

SCYNEXIS press release (SCYX): Q4 GAAP EPS of -$0.30 beats by $0.10.Revenue of $1.4M (+133.3% Y/Y) beats by $0.13M.SCYNEXIS ended Q4 2022 with cash, cash equivalents and…

At the same time, there are indicators that hold back the growth of Wall Street, for example, internal macro statistics. So, earlier, the US Department of Commerce lowered the estimate of the country''s GDP growth in the fourth quarter to 2.6% in annual terms (if GDP grew at the same pace for four consecutive quarters), the second estimate was 2.7%, and the first - 2.9% . In the third quarter, US GDP grew by 3.2% on an annualized basis. Data on the labor market also turned out to be worse than expected. US initial jobless claims for the week ending March 25 increased by 7,000 from the previous week to 198,000. The forecast was 196 thousand. At the close in the New York Stock Exchange, the Dow Jones was up 0.43%, the S&P 500 was up 0.57% and the NASDAQ Composite was up 0.73%. The leading performer among the Dow Jones index components today was Intel Corporation (NASDAQ:INTC), which gained 0.57 points or 1.81% to close at 32.09. Boeing Co (NYSE:BA) rose 3.07 points or 1.48% to close at 211.04.

SCYNEXIS (NASDAQ: SCYX ) brought in sales totaling $1.56 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 121.69%, resulting in a loss of $29.58 million. In Q2, SCYNEXIS brought in $1.32 million in sales but lost $13.35 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com

SCYNEXIS (SCYX), a biotech focused on treatments for fungal infections, announced Thursday that the FDA approved a second indication for its antifungal therapy Brexafemme.Accordingly,…

Scynexis (SCYX) said researchers from Case Western Reserve University in Cleveland were awarded a research grant of more than $3M by the National Institutes of Health ((NIH)) to…

SCYNEXIS Inc. (NASDAQ:SCYX) price remained unchanged on Friday, November 25, from its previous close. A look at the daily price movement shows that the last close reads $2.45, with intraday deals fluctuated between $2.43 and $2.47. The company’s 5Y monthly beta was ticking 1.89. Taking into account the 52-week price action we note that the … These Numbers Show Just How Powerful SCYNEXIS Inc. (NASDAQ: SCYX) Stock ‎Is Read More »

During the last session, SCYNEXIS Inc. (NASDAQ:SCYX)’s traded shares were 0.33 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $2.27, reflecting an intraday gain of 10.19% or $0.21. The 52-week high for the SCYX share is $8.10, that puts it down -256.83 … SCYNEXIS Inc. (NASDAQ: SCYX) Stock: Boom Or Bust? What Happens Next? Read More »

SCYNEXIS (SCYX), a biotech focused on treatments for fungal infections, announced Thursday that the FDA approved a second indication for its antifungal therapy Brexafemme.Accordingly,…

Scynexis (SCYX) said researchers from Case Western Reserve University in Cleveland were awarded a research grant of more than $3M by the National Institutes of Health ((NIH)) to…

SCYNEXIS Inc. (NASDAQ:SCYX) price remained unchanged on Friday, November 25, from its previous close. A look at the daily price movement shows that the last close reads $2.45, with intraday deals fluctuated between $2.43 and $2.47. The company’s 5Y monthly beta was ticking 1.89. Taking into account the 52-week price action we note that the … These Numbers Show Just How Powerful SCYNEXIS Inc. (NASDAQ: SCYX) Stock ‎Is Read More »

During the last session, SCYNEXIS Inc. (NASDAQ:SCYX)’s traded shares were 0.33 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $2.27, reflecting an intraday gain of 10.19% or $0.21. The 52-week high for the SCYX share is $8.10, that puts it down -256.83 … SCYNEXIS Inc. (NASDAQ: SCYX) Stock: Boom Or Bust? What Happens Next? Read More »

SCYNEXIS, Inc. (NASDAQ:NASDAQ:SCYX) Q3 2022 Results Conference Call November 9, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr.